908 Devices 2025 Q3 Earnings 48.9% Net Loss Reduction Narrows to $14.98M

908 Devices (MASS) reported Q3 2025 earnings, with revenue exceeding estimates but a wider-than-expected loss per share. The company reiterated full-year guidance, maintaining a $54–$56 million revenue range.

Revenue

908 Devices’ total revenue declined 3.5% year-over-year to $14.01 million in Q3 2025. Product sales accounted for $10.84 million, while services and contracts contributed $3.16 million. The sequential revenue increase of 8% reflects improved operational efficiency, though year-over-year declines persist amid market headwinds.

Earnings/Net Income

The company narrowed its net loss to $14.98 million in Q3 2025, a 48.9% improvement from $29.30 million in 2024 Q3. Earnings per share (EPS) improved to -$0.41 from -$0.84, marking a 51.2% reduction in losses. Despite the EPS miss relative to forecasts, the significant loss contraction underscores progress toward profitability.

Post-Earnings Price Action Review

Following the earnings report, 908 Devices’ stock dropped 5.68% in the latest trading day, 23.94% over the week, and 26.31% month-to-date. The sharp decline reflects investor concern over the wider-than-expected loss, despite revenue outperforming estimates. While the company’s 48.9% reduction in net losses signals operational improvements, the stock’s bearish momentum suggests short-term underperformance relative to broader market benchmarks.

CEO Commentary

CEO Kevin J. Knopp highlighted challenges in Q3 2025, including revenue declines and operational inefficiencies. Strategic priorities include accelerating R&D in core product lines, optimizing cost structures, and targeting emerging markets. The leadership team emphasized disciplined execution to bridge current performance gaps while maintaining cautious optimism about long-term opportunities.

Guidance

The company did not provide explicit forward-looking guidance for revenue, EPS, or CAPEX. Qualitative expectations focus on stabilizing operations, enhancing supply chain resilience, and aligning with evolving customer demand. The reiterated full-year revenue target of $54–$56 million reflects confidence in sustaining demand for handheld chemical analyzers.

Additional News

908 Devices announced the acquisition of KAF Manufacturing Company, Inc., a precision machining firm, to strengthen its supply chain for FTIR components. Earlier in 2025, the company divested its desktop portfolio to Repligen Corporation for $70 million, a key step in sharpening its strategic focus on handheld markets. Additionally, the acquisition of RedWave Technology’s FTIR products in April 2024 expanded its capabilities in chemical detection.